Gilead wins Chinese approval for Epclusa, but the emerging market is getting crowded
admin 30th May 2018 Uncategorised 0Epclusa was just greenlighted by China’s Drug Administration. For hepatitis C patients in China, it means the first pangenotypic treatment will soon be available. But for Gilead, the new market addition might be too little, too late.
More: Gilead wins Chinese approval for Epclusa, but the emerging market is getting crowded
Source: fierce